Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.

A HafnerP D GhislainR KovácsR BatchelorAlexander C KatoulisB KirbyH BanayanM Schonbrun

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

In this real-world setting, adalimumab treatment of moderate-to-severe HS resulted in decreased disease severity and improvements in QoL and productivity. Response to adalimumab was rapid (within 12 weeks) and sustained (52 weeks). No unexpected safety signals were reported.

Keyphrases

hidradenitis suppurativa
rheumatoid arthritis
juvenile idiopathic arthritis
gestational age
climate change
early onset
high intensity
disease activity